Glaukos Sets $1B Revenue Target After Record Q3
Glaukos Corp. (GKOS) reported Q3 revenue of $211M, up 58% YoY, and raised 2026 guidance to $775M-$785M. The company set a $1B revenue target for 2027, despite potential Medicare coverage restrictions for iDose TR. Shares rose 33% post-earnings. Alignment Healthcare (ALHC) lowered its 2023 adjusted gross profit and EBITDA guidance due to higher medical costs and claims volatility.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise drove a 33% share surge, indicating strong short‑term buying interest.
Market read
The news provides a clear catalyst for GKOS price movement and highlights sector momentum in eye‑care therapeutics.
What to watch
Potential regulatory constraints on iDose TR reimbursement may limit the $1B target.
Background
Glaukos posted a record Q3, beating estimates and raising guidance, then outlined a $1B revenue outlook for 2027 despite possible Medicare coverage changes.
Ticker impact
Glaukos reported Q3 results and raised full-year 2026 revenue guidance, then previewed a $1B 2027 target.
likely upward pressure as the market prices in the higher guidance and revenue target.
The earnings beat and guidance lift are fresh facts that moved the stock sharply.
Market effects
Strong growth in glaucoma and keratoconus treatments may boost the ophthalmology sector.
Positive for US biotech and medical device investors.
Limited to niche eye‑care market.
Counterpoint
Medicare coverage risk for iDose TR could curb revenue upside.
Key entities
- CompanyGlaukos Corp.
Ophthalmic drug and medical technology company.
